Lung Non-Small Cell Carcinoma with Genetic Abnormalities

subtype

Identifier: CI-CAN-00005823
Entity page: /cancer/lung-non-small-cell-carcinoma-with-genetic-abnormalities ↗
Edges: 49

Neighbours: 16 drugs10 trials
Drawn: 26 of 26 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,147 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Lung Non-Small Cell Carcinoma with Genetic Abnormalities approved for …APPROVED_FORderived4 of 4
← approved for	Taletrectinibsmall molecule FDA (US) · approved · 2025-06-11 · IBTROZI ® (taletrectinib) is indicated for the treatment of adult patients with locally advanced or metastatic ROS1 -positive non-small cel…	—	approved	ROS1-Positive Lung Non-Small Cell Carcinoma	1	Regulatory	openfda	graph →
← approved for

Lung Non-Small Cell Carcinoma with Genetic Abnormalities investigated in trials for …INVESTIGATED_IN_TRIALSderived14 of 14
→ investigated in trials for	Lorlatinibsmall molecule 7 trials (5 active) · roll-up of the cancer and its descendants	—	—	Lung Non-Small Cell Carcinoma with Genetic Abnormalities	7	Observed	clinicaltrials	graph →
→ investigated in trials for	Ceritinibsmall molecule 4 trials (1 active) · roll-up of the cancer and its descendants	—	—	Lung Non-Small Cell Carcinoma with Genetic Abnormalities	4	Observed	clinicaltrials	graph →
→ investigated in trials for	Alectinibsmall molecule 2 trials (0 active) · roll-up of the cancer and its descendants	—	—	Lung Non-Small Cell Carcinoma with Genetic Abnormalities	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Crizotinibsmall molecule 2 trials (0 active) · roll-up of the cancer and its descendants	—	—	Lung Non-Small Cell Carcinoma with Genetic Abnormalities	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Brigatinibsmall molecule 1 trials (0 active) · roll-up of the cancer and its descendants	—	—	Lung Non-Small Cell Carcinoma with Genetic Abnormalities	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Camrelizumabmonoclonal antibody 1 trials (0 active) · roll-up of the cancer and its descendants	—	—	Lung Non-Small Cell Carcinoma with Genetic Abnormalities	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Carboplatinsmall molecule 1 trials (0 active) · roll-up of the cancer and its descendants	—	—	Lung Non-Small Cell Carcinoma with Genetic Abnormalities	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Ensartinibsmall molecule 1 trials (1 active) · roll-up of the cancer and its descendants	—	—	Lung Non-Small Cell Carcinoma with Genetic Abnormalities	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Momelotinibsmall molecule 1 trials (0 active) · roll-up of the cancer and its descendants	—	—	Lung Non-Small Cell Carcinoma with Genetic Abnormalities	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Nivolumabmonoclonal antibody 1 trials (1 active) · roll-up of the cancer and its descendants	—	—	Lung Non-Small Cell Carcinoma with Genetic Abnormalities	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Paclitaxelsmall molecule 1 trials (0 active) · roll-up of the cancer and its descendants	—	—	Lung Non-Small Cell Carcinoma with Genetic Abnormalities	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Pemetrexedsmall molecule 1 trials (0 active) · roll-up of the cancer and its descendants	—	—	Lung Non-Small Cell Carcinoma with Genetic Abnormalities	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Taletrectinibsmall molecule 1 trials (0 active) · roll-up of the cancer and its descendants	—	—	Lung Non-Small Cell Carcinoma with Genetic Abnormalities	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Trametinibsmall molecule 1 trials (0 active) · roll-up of the cancer and its descendants	—	—	Lung Non-Small Cell Carcinoma with Genetic Abnormalities	1	Observed	clinicaltrials	graph →

Lung Non-Small Cell Carcinoma with Genetic Abnormalities investigated in trials for …INVESTIGATED_IN_TRIALSderived14 of 14

→ investigated in trials for

Lorlatinibsmall molecule

7 trials (5 active) · roll-up of the cancer and its descendants

—

Lung Non-Small Cell Carcinoma with Genetic Abnormalities

Observed

Lung Non-Small Cell Carcinoma with Genetic Abnormalities studied in …STUDIED_INderived10 of 31show all (up to 200)
→ studied in	NCT05987956Phase 2/Phase 3 · active not recruiting Pharmacogenomics IND SNP Clinical Trial - Alectinib and Single Nucleotide Polymorphisms · condition mapped ALIAS · 31 trials mapped (14 active)	—	—	ALK-Positive Lung Non-Small Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06834074available Expanded Access Program of Neladalkib (NVL-655) for Patients With Advanced ALK+ NSCLC or Other ALK+ Solid Tumors · condition mapped ALIAS · 31 trials mapped (14 active)	—	—	ALK-Positive Lung Non-Small Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07617337Phase 1 · recruiting AQUA07 in Patients With ALK-Positive Non-Small Cell Lung Cancer · condition mapped ALIAS · 31 trials mapped (14 active)	—	—	ALK-Positive Lung Non-Small Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT02393625Phase 1 · active not recruiting Study of Safety and Efficacy of Ceritinib in Combination With Nivolumab in Patients With ALK-positive Non-small Cell Lung Cancer · condition mapped ALIAS · 31 trials mapped (14 active)	—	—	ALK-Positive Lung Non-Small Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07567352active not recruiting A Study to Learn About Patients With Non-Small Cell Lung Cancer (NSCLC) Who Took Lorlatinib as Their First Treatment · condition mapped ALIAS · 31 trials mapped (14 active)	—	—	ALK-Positive Lung Non-Small Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07491497Phase 1/Phase 2 · recruiting A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC · condition mapped ALIAS · 31 trials mapped (14 active)	—	—	ALK-Positive Lung Non-Small Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06797362available Expanded Access Program of Zidesamtinib (NVL-520) for Patients With Advanced ROS1+ NSCLC or Other ROS1+ Solid Tumors · condition mapped ALIAS · 31 trials mapped (14 active)	—	—	ROS1-Positive Lung Non-Small Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07784959Phase 1 · recruiting Study of NXP900 With Lorlatinib in ALK+ Lung Cancer · condition mapped ALIAS · 31 trials mapped (14 active)	—	—	ALK-Positive Lung Non-Small Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07771764Phase 2 · not yet recruiting A Multicenter Exploratory Clinical Study of Iruplaltinib Combined With Pemetrexed as Neoadjuvant Therapy for Resectable ALK-Positive Non-Squamous Non-Small Cell Lung Cancer · condition mapped ALIAS · 31 trials mapped (14 active)	—	—	ALK-Positive Lung Non-Small Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07750704Phase 2 · not yet recruiting Lorlatinib Plus Sacituzumab Tirumotecan With Peripheral ctDNA Guidance as First-Line Therapy for ALK Fusion-Positive NSCLC · condition mapped ALIAS · 31 trials mapped (14 active)	—	—	ALK-Positive Lung Non-Small Cell Carcinoma	1	Observed	clinicaltrials	graph →

Radial view

Every edge, grouped by relationship

Strongest chains